The Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database
|
|
- Gwendoline Butler
- 5 years ago
- Views:
Transcription
1 LIVER TRANSPLANTATION 12: , 2006 ORIGINAL ARTICLE The Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database Victor Navarro, 1 Steven Herrine, 1 Charles Katopes, 1 Beth Colombe, 2 and C. Victor Spain 3 1 Department of Medicine, Gastroenterology and Hepatology, Jefferson Medical College, 2 Department of Tissue Typing, Thomas Jefferson University Hospital, and 3 Jefferson College of Graduate Studies, Thomas Jefferson University, Philadelphia, PA The purpose of this study was to explore the relationship between human leukocyte antigen (HLA) compatibility and liver transplantation outcomes by analyzing the effect of HLA compatibility on 5-year graft survival. We analyzed first liver transplants between 1987 and 2002 in the Organ Procurement and Transplantation Network (OPTN) database, where A, B, or DR loci data were available. Graft failure was defined as retransplantation or death from transplant-related cause. We evaluated associations between total and locus-specific match levels and 5-year graft survival. Multivariable Cox proportionalhazard models were used to evaluate statistical interactions and adjust for the effect of potential confounders. Among 29,675 first-time transplants, the overall degree of HLA match had no effect on 5-year graft survival, even after controlling for potential confounders. Univariate and multivariable analyses showed that the 0 HLA antigen mismatch cohort of patients had higher 5-year graft failure rates than the other 6 antigen mismatch groups. However, this occurred in a small group with a disproportionately large number of live donors and split-liver recipients. When these recipients were excluded from the analysis, the effect was no longer seen. Finally, multivariable, locus-specific analyses showed no association between 5-year graft survival and degree of match/mismatch and the A, B, or DR loci. In conclusion, this careful examination of the OPTN database, with respect to HLA match or mismatch and liver graft survival, reaffirms that HLA matching has no clinically significant impact on this outcome. Liver Transpl 12: , AASLD. Received August 21, 2005; accepted November 16, The benefit of human leukocyte antigen (HLA) compatibility in kidney, heart, and bone marrow transplantation is indisputable. Closer compatibility leads to a lower incidence of acute and chronic rejection and improved graft survival. 1,2 As a result, HLA compatibility between donor and recipient is viewed as an important determinant of transplantation outcomes. Using HLA phenotypes to match donor with recipient when feasible has become standard practice. In liver transplantation, HLA compatibility between the donor and recipient has been largely of academic interest. That is to say, donor and recipient HLA compatibility is not considered to have a clinically significant effect on liver transplant outcomes. Histocompatibility, therefore, does not factor into donor and recipient matching. Nonetheless, the notion that the degree of HLA matching may have an adverse impact on graft or patient outcomes has been explored by several investigators. Most importantly, Markus et al. observed, in a large cohort of liver transplantation recipients, that greater HLA compatibility at the A and DR loci was associated with a higher incidence of nonrejection-related graft failure. 3 This group also observed a higher incidence of graft failure due to rejection with a lower degree of HLA compatibility. These seminal observations introduced the possibility of a dualistic role of HLA in liver transplantation that is, protection from rejection with greater donor and recipient compatibil- Abbreviations: HLA, human leukocyte antigen; UNOS, United Network for Organ Sharing; OPTN, Organ Procurement and Transplantation Network; PH, proportional hazards; HCV, hepatitis C virus. Address reprint requests to: Victor J. Navarro, MD, 132 South 10th St., Suite 480 Main, Philadelphia, PA Telephone: ; FAX: ; victor.navarro@jefferson.edu DOI /lt Published online in Wiley InterScience ( American Association for the Study of Liver Diseases.
2 HLA COMPATIBILITY AND LIVER TRANSPLANT OUTCOMES 653 ity, but a higher risk of nonrejection-related graft failure under the same conditions. 3 Subsequently, Donaldson et al. confirmed the observation that class I compatibility exerted a dual effect on graft survival. 4 Finally, Neumann et al. found lower rejection rates in closer HLAmatched transplants; however, graft survival in transplants for primary sclerosing cholangitis was significantly impaired in the presence of increasing HLA-DR compatibility. Similar results were noted for autoimmune hepatitis, although the findings were not statistically significant. 5 The question of whether donor and recipient HLA compatibility has any clinically significant impact on liver transplant outcomes, namely graft survival, has not been asked using the vast body of data available through the United Network for Organ Sharing (UNOS) Organ Procurement and Transplantation Network (OPTN) database. This resource, by virtue of its size, affords an opportunity to search for an effect of donor and recipient HLA compatibilities on transplant outcomes that smaller cohorts may fail to detect. In addition, confounding variables and other factors that may affect outcomes can also be examined in the context of the degree of HLA matching. Thus, the primary aim of this study was to evaluate liver transplant graft survival as a function of HLA match and mismatch using the UNOS database of donor and recipient pairs. MATERIALS AND METHODS Study Cohort This was a retrospective cohort study of patients represented in the OPTN database as of October 14, To be included in the analysis, the transplantation must have been the first for that recipient, it must have been completed between 1987 and June, 2002, and complete information needed to be available for the relevant outcome and confounding variables used in the analysis. UNOS randomly changes the transplant dates by up to 180 days (in either direction) to preserve patient anonymity. Therefore, these transplantations could have occurred as late as December, The OPTN database contained 61,148 liver transplants performed in 55,193 recipients. From these, a total of 29,695 first-time transplants met our selection criteria for 1 or more of the analyses; 28,608, 29,575, 29,571 and 28,735 met the selection criteria for the combined match/mismatch, A, B, and DR locus-specific analyses, respectively. Of the first-time recipients excluded from the analysis, 21,965 (86.1%) were missing data for all 3 HLA loci, another 2,980 (11.7%) had transplantations outside of the included date range, another 98 (0.4%) were missing data on graft failure status or timing, and another 455 (1.8%) were missing 1 or more candidate-confounding variables. Definitions Our primary outcome was graft failure during the first 5 years after transplantation, with graft failure defined as retransplantation or death from a transplant-related cause. The latter included death attributable to 1 of 9 UNOS categories of graft failure: biliary tract complications, graft vs. host disease, hepatitis, other infections, primary graft failure, other recurrent disease of hepatic origin, rejection, vascular thromboses, and other graft failure. Graft failure did not include any deaths occurring more than 5 years after transplantation. We chose to limit our analyses to the first 5 years after transplantation due to our assumption that any clinically significant sequelae of HLA compatibility or incompatibility would have occurred within this time period. Individual causes of graft failure could not be evaluated with the complete data set, as data on these causes were often missing. Of the 3,858 graft failures meeting selection criteria, for example, 1,622 (42.3%) and 1,683 (43.2%) had missing or unknown data for the variables indicating biliary disease or de novo hepatitis, respectively, as a contributing cause of failure. Similarly, we could not evaluate rejection as a specific outcome as 87.0% of recipients included in 1 or more analyses (25,840 of 29,695) were missing data on both acute and chronic rejection. Survival time was defined as the time from first transplant to date of graft failure. Patients with intact grafts 5 years from transplantation were censored at that time point. Patients lost to follow-up during the first 5 years after transplantation were censored at the last recorded medical visit. Recipients who died during the first 5 years after transplantation were included in the analysis but censored at the time of death if the cause of death was trauma or suicide, cardiovascular or cerebrovascular disease, gastrointestinal bleeding, nonhepatic malignancy, generalized sepsis, or pulmonary and renal failure. Although several of these causes of death may have been related to the transplant process or complications of immunosuppression, they were censored because we considered it unlikely that HLA compatibility would play a role in a substantial number of patients with these disease processes. Therefore, classification of these non-immune-mediated causes of death as being directly graft related would potentially have diluted or masked the effect of HLA matching on graft survival. Statistical Analyses We conducted 5 sets of analyses. In the first 2, we assessed the association between graft survival and combined HLA match or mismatch levels at 3 loci. For these 2 sets, total HLA matches or mismatches were counted, each with a possible range from 0 to 6 (2 possible alleles at each of 3 loci: A, B, or DR). Because of the small number of recipients having 6 matches with their donors, those with 5 or 6 HLA matches were collapsed into a single category during analysis of HLA matches. In contrast, all 7 categories of mismatches (0 to 6 mismatches) were kept in the mismatch analysis. In the other 3 sets of analyses, we evaluated the association between graft survival and degree of match/mismatch at each locus (A, B, DR)
3 654 NAVARRO ET AL. individually. For each locus, recipients were placed into 1 of 5 categories based on their match/mismatch level with the donor: 2 matches and 0 mismatches, 1 match and 0 mismatches (homozygous donor), 1 match and 1 mismatch, 0 matches and 1 mismatch (homozygous donor), 0 matches and 2 mismatches. Matches and mismatches were always counted from the recipient s perspective. For all 5 sets of analyses, graft survival was estimated using the Kaplan-Meier method and univariate comparisons were made using the log-rank test. 6 For each of the 5 sets, a global test of significance for all match/mismatch categories was conducted (e.g., testing the overall effect of match level for A locus) and then individual match categories (e.g., 2 A locus matches and 0 mismatches) were evaluated. Multivariable Cox proportional hazard (PH) models were developed to evaluate statistical interactions and adjust for the effect of potential confounding variables. 7 In the PH models, we assessed statistical interactions between HLA match/mismatch level and 8 other variables: diagnosis of autoimmune disease (autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis, graft vs. host disease secondary to non liver transplant), diagnosis of viral hepatitis, donor and recipient sex, donor and recipient race, age group, and treatment year. We then evaluated the effect of candidate confounding variables: recipient diagnosis, year of transplant, concurrent multiorgan transplantation, donor type (live vs. cadaveric), donor-recipient ABO blood type compatibility, cytomegalovirus infection, time on waiting list before transplantation, medical condition prior to transplantation (in intensive care unit, other hospitalization, or not hospitalized), as well as all 8 variables listed in the interaction evaluation. We began with a main-effects model and evaluated the statistical significance of the interaction terms one at a time. Then, confounding was assessed using a backward elimination algorithm. Candidate confounding variables were retained in final models when removing them changed one or more coefficient(s) for the HLA match/mismatch level by more than 10%. Statistical significance of the HLA match/mismatch level was assessed again in the final model. Separate models were developed to assess confounding by hepatitis C virus (HCV) and cytomegalovirus status, using the records from 1994 through 2002 for which HCV and cytomegalovirus test results were available. In the PH regression, all statistical significance was determined using the likelihood ratio test. 8 A P of 0.05 was considered statistically significant. For each of the 5 sets of analyses, PH models were developed for the analysis of overall effect (e.g., overall effect of total HLA mismatches). Individual match/mismatch levels (e.g., having 2 mismatches) were evaluated with PH models only if the log-rank test for that level was significant. All analyses were conducted with SAS version 8.2 (SAS Institute Inc., Cary, NC). RESULTS Characteristics of and Graft Survival in the Final Study Cohort Among the 29,695 recipients included in 1 or more of the analyses, the majority was white and male and the most common diagnosis was viral hepatitis (Table 1). Among the 3,858 (13%) recipients with graft failure in the first 5 years, 1,001 (3.4%) died of a liver-related cause without retransplantation, and 2,857 (9.6%) received a second transplant. The median graft survival time was 271 days (range, 0 to 1,821 days) for those who died and 31 days (range, 0 to 1,818 days) for those who received a second transplant. Combined HLA Match and Mismatch Analyses Among the 28,608 recipient-donor pairs analyzed to assess the effect of combined HLA compatibility on graft survival, the median number of HLA matches was 1 (range, 0 to 6), and the median number of mismatches was 5 (range, 0 to 6). In the univariate analyses, the tests of global effect of HLA match or HLA mismatch on graft survival were not significant (P 0.24 and 0.12, respectively). When testing individual categories, 1 level of HLA mismatch was statistically different from the others; the category of recipients with 0 HLA mismatches had significantly higher 5-year graft failure (19.3%) when compared to all other levels of HLA mismatch (12.9% failure, P 0.02) (Table 2). This category, however, had only 114 recipients, representing 0.4% of all recipients. These recipients were clearly different in other ways from the general recipient population, with a significantly higher proportion of live donors (32% vs. 2% in other mismatch categories) and higher proportion receiving partial or split-organ transplants (33% vs. 4% in other mismatch categories). In the multivariable analysis, the effect of 0 HLA mismatches remained statistically significant (adjusted P 0.03; hazard ratio 1.59; 95% confidence interval, 1.04, 2.43). Considering the potential effect of partial organ transplantation, we repeated this analysis after excluding these recipients and found the effect of 0 HLA mismatches to no longer be statistically significant (log-rank test; P 0.08). In the other multivariable analyses, we found no significant interactions between HLA match or mismatch and ethnicity, gender, transplantation during childhood, or recipient diagnoses of viral hepatitis or autoimmune disease. There was a statistically significant interaction, however, between HLA match level and the age group of recipients 50 years old (P 0.01). The interaction between combined HLA match level and age group was driven mostly by a differential graft failure rate for those with 2 matches. In recipients 50 years of age, those with 2 matches had a higher failure rate (16.1%) than those with 0, 1, 3, 4, 5, or 6 matches in the same age group (14.7% failure rate). In contrast, recipients 50 years of age had a lower failure rate (9.2%) with 2 matches when compared to those in this age group with 0, 1, 3, 4, 5, or 6 matches (10.7% failure). As
4 HLA COMPATIBILITY AND LIVER TRANSPLANT OUTCOMES 655 TABLE 1. Characteristics of Transplant Recipients and Donors (N 29,695 Procedures) Characteristic Frequency Percent of Total Recipient Gender Female 12, Male 17, Donor Gender Female 11, Male 18, Recipient race White, non-hispanic 22, Black, non-hispanic 2, Hispanic 3, Asian Other Multiracial, non-hispanic Unknown Donor race White, non-hispanic 23, Black, non-hispanic 3, Hispanic 2, Asian Other Multiracial, non-hispanic Unknown Treatment Year* , , , , , , Pretransplantation diagnosis AHN, cryptogenic Alcohol induced 5, Autoimmune 5, Cirrhosis, cryptogenic 2, Hepatic malignancy 1, Metabolic, genetic 3, Secondary biliary cirrhosis Toxic Unknown 1, Viral 8, Abbreviation: AHN, acute hepatic necrosis. *In de-identification procedures, date of transplantation is shifted by as much as 180 days. the locus-specific analysis will show, no single locus accounted for this effect. Given the illogical pattern of this interaction and the lack of a biological mechanism that would explain it, we considered it likely that its statistical significance was due to a Type I error. Therefore, these interaction terms were not carried further in multivariable models that evaluated combined HLA match level. After adjusting for potential confounding, we found no significant association between combined HLA match or mismatch level and 5-year graft survival (adjusted P 0.37 and 0.29, respectively, in final Cox PH model). Locus-Specific Analyses In univariate analyses of locus-specific match level, only 1 comparison was statistically significant; for HLA-A, the global test of effect was not significant, but recipients with 2 A-locus mismatches were found to have slightly higher 5-year graft failure rates (13.4%, Table 2) when compared to those with 0 or 1 mismatches (12.6% failure, log-rank test, P 0.03). In multivariable analyses, we found no significant interactions for any of the 3 locus-specific analyses, A locus included. Similarly, we found no association between the match/mismatch level at the B and DR loci and 5-year graft survival, even after adjusting for confounding (adjusted P 0.86 and 0.85, respectively, in final Cox PH model). In multivariable analysis, the global effect of HLA-A locus match/mismatch was not significant (adjusted P 0.33) and the effect of having 2 A-locus mismatches was no longer significant (adjusted
5 656 NAVARRO ET AL. TABLE 2. 5-Year Graft Failure by Donor-Recipient HLA Match Level at A, B, and DR Loci Match Categories Frequency in Match Level (% of total) Frequency With Graft Failure (% in match level) Graft Failure Incidence (per 100 person-years) Number of combined HLA mismatches (N 28,608) (0.4) 22 (19.3) 8.28* (0.7) 23 (10.9) ,095 (3.8) 129 (11.8) ,773 (13.2) 482 (12.8) ,603 (26.6) 957 (12.6) ,209 (35.7) 1,344 (13.2) ,603 (19.6) 737 (13.2) 4.48 Number of combined HLA matches (N 28,608) 0 8,821 (30.8) 1,168 (13.2) ,146 (39.0) 1,422 (12.8) ,791 (20.2) 748 (12.9) ,327 (8.1) 296 (12.7) (1.4) 42 (10.1) or (0.4) 18 (16.5) 7.44 A locus matches, mismatches (N 29,575) 2 matches, 0 mismatches 765 (2.6) 94 (12.3) match, 0 mismatches 1,521 (5.1) 196 (12.9) match, 1 mismatch 9,893 (33.4) 1,249 (12.6) matches, 1 mismatch 3,026 (10.2) 380 (12.6) matches, 2 mismatches 14,370 (48.6) 1,927 (13.4) 4.49 B locus matches, mismatches (N 29,571) 2 matches, 0 mismatches 338 (1.1) 47 (13.9) match, 0 mismatches 458 (1.5) 64 (14.0) match, 1 mismatch 6,458 (21.8) 830 (12.9) matches, 1 mismatch 2017 (6.8) 268 (13.3) matches, 2 mismatches 20,300 (68.7) 2,638 (13.0) 4.32 DR locus matches, mismatches (N 28,735) 2 matches, 0 mismatches 818 (2.9) 110 (13.4) match, 0 mismatches 1,038 (3.6) 140 (13.5) match, 1 mismatch 9,436 (32.8) 1,198 (12.7) matches, 1 mismatch 3,087 (10.7) 391 (12.7) matches, 2 mismatches 14,356 (50.0) 1,868 (13.0) 4.38 *Significant difference, P 0.02 univariate analysis, P 0.08 after excluding split/partial transplants. Significant difference, P 0.03 univariate, P 0.12 multivariable analyses. P 0.12; hazard ratio 1.05; 95% confidence interval, 0.99, 1.12). DISCUSSION In this study, we hoped to determine decisively, using the OPTN liver transplant database, whether HLA matching in liver transplantation has any impact on graft survival and whether this impact differed in recipients with autoimmune and viral diagnoses. As will be discussed, several limitations to the database must be considered when comparing our findings to those of others. Nevertheless, the large number of transplant recipients captured in the database afforded increased statistical power for many comparisons that had not been possible in previous studies including evaluation of statistical interactions. Similarly, the large number of variables in the database allowed us to control for potential confounding by many important determinants of graft survival. In our analysis, we found no association between the degree of combined HLA matching and graft survival. When evaluating HLA mismatches in multivariable analysis, the only statistically different subgroup was the one with 0 HLA mismatches. However, these recipients represented only 0.4% of all recipients and they were clearly different from the general recipient population in that there was a large proportion of live donor and partial graft recipients. When we excluded these recipients from the analyses, the 0 mismatch group was no longer different. In the univariate
6 HLA COMPATIBILITY AND LIVER TRANSPLANT OUTCOMES 657 locus-specific analysis, we identified a higher rate of graft failure with 2 A locus mismatches; however, this relationship did not persist in multivariable analysis. The effect of HLA compatibility on liver transplantation outcomes has been the focus of several studies spanning more than a decade. Earlier studies identified various effects of HLA compatibility on liver transplant outcomes. 3,4,5 Markus et al. in 1988 demonstrated that increased HLA compatibility was associated with diminished graft survival, although transplant rejection was reduced. 3 Neumann et al., in their study of 924 patients, found that the total number of HLA matches had no influence on overall graft survival, and acute cellular rejection was reduced with increased matching. When analyzing survival based on etiology of liver disease, survival was significantly reduced in transplants for primary sclerosing cholangitis in the presence of 1 or 2 HLA-DR compatibilities. Similar trends were noted for autoimmune hepatitis, although not statistically significant. 5 Knechtle et al. identified that a mismatch at the HLA A locus correlated with graft loss, and that better matching improved patient and graft survival. 9 These studies, point out that HLA matching and mismatching play a dual role in liver transplantation, on the one hand enhancing graft survival but, on the other hand, increasing the risk of rejection with increasing levels of HLA match, as first suggested by Markus. 3 However, these studies also highlight the complex interplay of HLA compatibility and success of the graft. Investigators have also found that HLA compatibility may affect the recurrence of hepatitis B and C viruses following liver transplantation. Gaur et al. found that compatibility at the HLA DQB locus correlated with recurrent HCV. 10 In another study, compatibility of class I antigens correlated with recurrent HBV. 11 Finally, Manez et al. found that matching at the HLA B locus increased the risk of recurrent viral hepatitis. 12 In our study, we tested the hypothesis that HLA matching might have a differential effect for recipients with prior viral hepatitis and also introduced a series of controls for potential confounding by HCV or cytomegalovirus. We could not directly evaluate recurrent viral hepatitis, and we had no data on HLA DQB. However, our results suggest that if an association between HLA matching at A, B, and DR loci and recurrent viral hepatitis exists, this association did not result in a significant difference in graft survival. The apparent discrepancies between our results and previously published studies may, in part, be the result of limitations of the OPTN database. In particular, given the anonymity of the data, we could not control for factors that may have impacted the outcome, such as immunosuppression handling and surgical technique. Also, single-center data may have an advantage over OPTN data, in that patients may have received similar care in a given center and investigators had the opportunity to verify diagnoses. Moreover, the OPTN data allowed us to consider only a part of the HLA system that is, HLA A, B (Class I) and DR (Class II). Others have shown a potential effect of other HLA antigens or antibody reactivity in graft survival Also, some have shown an effect of HLA G in rejection. 13,16 These limitations notwithstanding, our study has the advantage of greatly increased statistical power with controls to examine various potential confounding and interacting variables. This paper reviews the data of patients experiencing liver graft loss and asks, Does HLA matching at the A, B, and DR loci, either combined or at the locus-specific level, have an effect on graft survival? To answer this question fully, one must consider the possibility that any immunological effects of HLA mismatching could be masked by other nonimmunological processes that may affect graft survival, such as recurrent liver disease, surgical technique, technical complication, and immunosuppression handling. Any of these factors may have an effect on graft outcome. It is also possible that HLA compatibility could have a differential effect for different types of graft failure in live donor or partial transplantation, as our data suggest. The data necessary to answer some of these questions are either not contained within or incomplete in the existing UNOS database. Thus, we can conclude that HLA matching or mismatching had no clinically significant impact on liver graft survival in cadaveric liver transplantation. However, while graft loss statistics may show no impact in cadaveric liver transplantation, the question of the effect of HLA matching in live donor transplantation and on the physiological success of the organ remains unanswered. This study of UNOS data will be extended to include the effects of the HLA compatibility on graft outcome in individual disease entities within our own center, for which data are available. ACKNOWLEDGEMENT The authors thank Maricruz Velez, MPH for her assistance in preparation of the manuscript. REFERENCES 1. Opelz G, Wujciak T, Dohler B, Scherer S, Mytilineos J. HLA compatibility and organ transplant survival. Collaborative transplant study [review] Rev Immunogenet 1999;1: Takemoto S, Port FK, Claas FH, Duquesnoy RJ. HLA matching for kidney transplantation. Hum Immunol 2004; 65: Markus BH, Duquesnoy RJ, Gordon RD, Fung JJ, Vanek M, Klintmalm G, et al. Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation 1988;46: Donaldson P, Underhill J, Doherty D, Hayllar K, Calne R, Tan KC, et al. Influence of human leukocyte antigen matching on liver allograft survival and rejection: The dualistic effect. Hepatology 1993;17: Neumann UP, Guckelberger O, Langrehr JM, Lang M, Schmitz, V, Theruvath T, et al. Impact of human leukocyte antigen matching in liver transplantation. Transplantation ;75: Hosmer DW, Lemeshow S. Applied Survival Analysis. New York: John Wiley & Sons, Inc; 1999: Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute, Inc.;1995:
7 658 NAVARRO ET AL. 8. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. New York: Van Nostrand Reinhold; 1982: Knechtle SJ, Kalayolu M, D Alessandro AM, Mason B, Pirsch JD, Sollinger HW, et al. Histocompatibility and liver transplantation. Surgery 1993;114: Gaur L, Nelson K, Gretch D, Wile N, Strong D, Corey L, et al. Donor-recipient match at the HLA DQB locus is associated with recurrence of chronic hepatitis following liver transplantation for end stage hepatitis C. Hum Immunol 1994;40: Calmus Y, Honnoun L, Doussett B, Wolff P, Miguet P, Doffoel M, et al. HLA class I matching is responsible for the hepatic lesions in viral B hepatitis after hepatic transplantation. J Hepatol 1989;9: Manez, R, Mateo R, Tabasco J, Kusne S, Starzl TE, Duquesnoy RJ. The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation. Transplantation 1995;59: Creput C, Durrbach A, Menier C, Guettier C, Samuel D, Dausset J, et al. Human leukocyte antigen-g (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 2003;39: Carco R, Vargas V, Balsells J, Lazaro J, Murio E, Jaurerrieta E, et al. Influence of anti-hla antibodies and positive crossmatch on survival and graft rejection in human liver transplantation. J Hepatol 1996;24: Nikaein A, Backman L, Jennings L, Levy M, Goldstein R, Gonwa T, et al. HLA compatibility and liver transplant outcome. Improved patient survival by HLA and crossmatching. Transplantation 1994;58: Creput C, Le Friec G, Bahri R, Amiot L, Charpentier B, Carosella E, et al. Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: possible implications for monitoring patients. Hum Immunol 2003;64:
ORIGINAL ARTICLE. Received April 30, 2007; accepted June
LIVER TRANSPLANTATION 13:1405-1413, 2007 ORIGINAL ARTICLE Human Leukocyte Antigen and Adult Living- Donor Liver Transplantation Outcomes: An Analysis of the Organ Procurement and Transplantation Network
More informationLiver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995
Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationWhat Is the Real Gain After Liver Transplantation?
LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;
More informationORIGINAL ARTICLE. Eric F. Martin, 1 Jonathan Huang, 3 Qun Xiang, 2 John P. Klein, 2 Jasmohan Bajaj, 4 and Kia Saeian 1
LIVER TRANSPLANTATION 18:914 929, 2012 ORIGINAL ARTICLE Recipient Survival and Graft Survival are Not Diminished by Simultaneous Liver-Kidney Transplantation: An Analysis of the United Network for Organ
More informationShould Pediatric Patients Wait for HLA-DR-Matched Renal Transplants?
American Journal of Transplantation 2008; 8: 2056 2061 Wiley Periodicals Inc. C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant
More informationMinimal But Significant Improvement in Survival for Non Hepatitis C Related Adult Liver Transplant Patients Beyond the One-Year Posttransplant Mark
LIVER TRANSPLANTATION 16:130-137, 2010 ORIGINAL ARTICLE Minimal But Significant Improvement in Survival for Non Hepatitis C Related Adult Liver Transplant Patients Beyond the One-Year Posttransplant Mark
More informationA %; 45%) , 60%; 3-4, 54%; 5-6, 57% [ P
Long-Term Outcome of Human Leukocyte Antigen Mismatching in Liver Transplantation: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database Vijayan
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationThe pediatric end-stage liver disease (PELD) score
Selection of Pediatric Candidates Under the PELD System Sue V. McDiarmid, 1 Robert M. Merion, 2 Dawn M. Dykstra, 2 and Ann M. Harper 3 Key Points 1. The PELD score accurately predicts the 3 month probability
More informationHong Kong Journal Nephrol of 2000;(2): Nephrology 2000;2(2): BR HAWKINS ORIGINAL A R T I C L E A point score system for allocating cadaver
Hong Kong Journal Nephrol of 2000;(2):79-83. Nephrology 2000;2(2):79-83. ORIGINAL A R T I C L E A point score system for allocating cadaveric kidneys for transplantation based on patient age, waiting time
More informationHLA HISTOCOMPATIBILITY AND LIVER TRANSPLANT SURVIVAL
HLA HISTOCOMPATIBILITY AND LIVER TRANSPLANT SURVIVAL Bernd H. Markus*, John J. Fung, Robert D. Gordon, Marian Vanek, Thomas E. Starzl, and Rene J. Duquesnoy From the Department of Surgery and the Division
More informationORIGINAL ARTICLE. Underlying Disease as a Predictor for Rejection After Liver Transplantation
ORIGINAL ARTICLE Underlying Disease as a Predictor for Rejection After Liver Transplantation Gabriela A. Berlakovich, MD; Susanne Rockenschaub, MD; Susanne Taucher, MD; Klaus Kaserer, MD; Ferdinand Mühlbacher,
More informationjournal of medicine The new england
The new england journal of medicine established in 1812 february 5, 2004 vol. 350 no. 6 Effect of Changing the Priority for HLA Matching on the Rates and Outcomes of Kidney Transplantation in Minority
More informationCOMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS
COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS A COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS KEVIN C. MANGE, M.D.,
More informationKidney transplantation is the treatment of choice
SPECIAL ARTICLES Evidence-based Organ Allocation* Stefanos A. Zenios, PhD, Lawrence M. Wein, PhD, Glenn M. Chertow, MD, MPH BACKGROUND: There are not enough cadaveric kidneys to meet the demands of transplant
More informationPancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry
American Journal of Transplantation 2016; 16: 688 693 Wiley Periodicals Inc. Brief Communication Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi:
More informationPOST TRANSPLANT OUTCOMES IN PSC
POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners
More informationHuman leukocyte antigen (HLA) matching has a beneficial
IMMUNOBIOLOGY AND GENOMICS Predicting the Immunogenicity of Human Leukocyte Antigen Class I Alloantigens Using Structural Epitope Analysis Determined by HLAMatchmaker Vasilis Kosmoliaptsis, 1,2 J. Andrew
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20898 holds various files of this Leiden University dissertation. Author: Jöris, Monique Maria Title: Challenges in unrelated hematopoietic stem cell transplantation.
More informationSylwia Mizia, 1 Dorota Dera-Joachimiak, 1 Malgorzata Polak, 1 Katarzyna Koscinska, 1 Mariola Sedzimirska, 1 and Andrzej Lange 1, 2. 1.
Bone Marrow Research Volume 2012, Article ID 873695, 5 pages doi:10.1155/2012/873695 Clinical Study Both Optimal Matching and Procedure Duration Influence Survival of Patients after Unrelated Donor Hematopoietic
More informationOrgan transplantation in Bulgaria
Cell Tissue Banking (28) 9:337 342 DOI 1.17/s1561-7-935-2 Organ transplantation in Bulgaria Elissaveta Naumova Æ Petar Panchev Æ Pencho J. Simeonov Æ Anastassia Mihaylova Æ Kalina Penkova Æ Petia Boneva
More informationResearch Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database
Transplantation Volume 2013, Article ID 269096, 7 pages http://dx.doi.org/10.1155/2013/269096 Research Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients:
More informationThe Effect of Donor Race on the Survival of Black Americans Undergoing Liver Transplantation for Chronic Hepatitis C
LIVER TRANSPLANTATION 15:1126-1132, 2009 ORIGINAL ARTICLE The Effect of Donor Race on the Survival of Black Americans Undergoing Liver Transplantation for Chronic Hepatitis C Phillip S. Pang, 1,2 * Ahmad
More informationImpact of Chronic Liver Disease and Cirrhosis on Health Utilities Using SF-6D and the Health Utility Index
LIVER TRANSPLANTATION 14:321-326, 2008 ORIGINAL ARTICLE Impact of Chronic Liver Disease and Cirrhosis on Health Utilities Using SF-6D and the Health Utility Index Amy A. Dan, 1,2 Jillian B. Kallman, 1,2
More informationSTEP-programme S-candiaT-ransplant kidney E-xchange P-rogramme (STEP) Version 1.8
STEP-programme S-candiaT-ransplant kidney E-xchange P-rogramme (STEP) Version 1.8 June 12, 2017 General guidelines Purpose To increase the likelihood of offering a suitable kidney graft to immunized (HI)
More informationDebate: HLA matching matters in children
Annual Congress 2018 14 th to 16 th March, the Brighton Centre, Brighton Debate: HLA matching matters in children Presenting the case for - Dr Jon Jin (JJ) Kim, Nottingham Richard & Ronald Herrick 23 Dec
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationHwm YI Yoo, * Ernest0 Molmenti, ' and PuulJ Tbuluvutb"
The Effect of Donor Body Mass Index on Primary Nonfunction, Retransplantation Rate, and Early and Patient Survival After Liver Transplantation Hwm YI Yoo, * Ernest0 Molmenti, ' and PuulJ Tbuluvutb" Previous
More informationHow to improve long term outcome after liver transplantation?
How to improve long term outcome after liver transplantation? François Durand Hepatology & Liver Intensive Care University Paris Diderot INSERM U1149 Hôpital Beaujon, Clichy PHC 2018 www.aphc.info Long
More informationLong-Term Renal Allograft Survival in the United States: A Critical Reappraisal
American Journal of Transplantation 2011; 11: 450 462 Wiley Periodicals Inc. C 2010 The Authors Journal compilation C 2010 The American Society of Transplantation and the American Society of Transplant
More information6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD?
6/19/212 KPD Webinar Series: Part 3 Demystifying the OPTN Kidney Paired Donation Pilot Program Unacceptable HLA antigens: The key to finding a compatible donor for your patient M. Sue Leffell, Ph.D. J.
More informationORIGINAL ARTICLE. Hung-Tien Kuo, 1,2 Erik Lum, 1 Paul Martin, 3 and Suphamai Bunnapradist ORIGINAL ARTICLE
ORIGINAL ARTICLE Effect of Diabetes and Acute Rejection on Liver Transplant Outcomes: An Analysis of the Organ rocurement and Transplantation Network/United Network for Organ Sharing Database Hung-Tien
More informationTreatment with Immunoglobulin Improves Outcome for Pediatric Liver Transplant Recipients
LIVER TRANSPLANTATION 15:1564-1569, 2009 ORIGINAL ARTICLE Treatment with Immunoglobulin Improves Outcome for Pediatric Liver Transplant Recipients John C. Bucuvalas, and Ravinder Anand, 2 Studies of Pediatric
More informationCorneal transplantation: HLA and age
L Aquila, 24 novembre 2012 Corneal transplantation: HLA and age Federico Genzano Besso*, Paola Magistroni, Piera Santoro*, Silvano Battaglio*, Raffaella Giacometti, Morteza Mansouri and Antonio Amoroso
More informationUEMS & EBS: DIVISION OF TRANSPLANT SURGERY
CURRICULUM AND SYLLABUS TRANSPLANTATION Module 1: Multi-organ retrieval Ability to evaluate donor suitability Ability to retrieve abdominal organs for transplantation Evaluation of donor/ organs suitability
More informationRemoving Patients from the Liver Transplant Wait List: A Survey of US Liver Transplant Programs
LIVER TRANSPLANTATION 14:303-307, 2008 ORIGINAL ARTICLE Removing Patients from the Liver Transplant Wait List: A Survey of US Liver Transplant Programs Kevin P. Charpentier 1 and Arun Mavanur 2 1 Rhode
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationPrevalence and Outcomes of Multiple-Listing for Cadaveric Kidney and Liver Transplantation
American Journal of Transplantation 24; 4: 94 1 Blackwell Munksgaard Copyright C Blackwell Munksgaard 23 doi: 1.146/j.16-6135.23.282.x Prevalence and Outcomes of Multiple-Listing for Cadaveric Kidney and
More informationViral Hepatitis And Liver Transplantation
Viral Hepatitis And Liver Transplantation Dr.Zeki KARASU Ege University Medical School Dep. Gastroenterology Hepatitis B 3-7 10 % HBV infection in liver transplant recipients, in western countries. 120
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationThe New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health
The New Kidney Allocation System: What You Need to Know Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health ~6% of patients die each year on the deceased donor waiting
More informationUpdate on Kidney Allocation
Update on Kidney Allocation 23rd Annual Conference Association for Multicultural Affairs in Transplantation Silas P. Norman, M.D., M.P.H. Associate Professor Division of Nephrology September 23, 2015 Disclosures
More informationTransplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation
Transplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation Titte R Srinivas, MD, FAST Medical Director, Kidney and Pancreas Transplant Programs Objectives: Describe trends
More informationThe New Kidney Allocation Policy: Implications for Your Patients and Your Practice
The New Kidney Allocation Policy: Implications for Your Patients and Your Practice Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Explain
More informationE nd stage liver disease due to hepatitis C virus infection
248 LIVER DISEASE Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C M Wali, R F Harrison, P J Gow, D Mutimer... Gut 2002;51:248 252 See end of article for
More informationCRITICAL EVALUATION OF THE AMINO ACID TRIPLET-EPITOPE MATCHING CONCEPT IN CADAVER KIDNEY TRANSPLANTATION
902 TRANSPLANTATION Vol. 77, No. 6 has been observed. In this series with tacrolimus, we did not observe any episode of rejection during pregnancy, although there was a reduction in prednisone dosage and
More informationLe migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE
Le migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE Best Therapy for Kidney Re- Transplantation? PREVENTION!!!! Registries CTS OPTN UNOS USRDS SRTR
More informationThe Acceptable Mismatch program of Eurotransplant.
The Acceptable Mismatch program of Eurotransplant. Frans Claas Leiden University Medical Center Eurotransplant Reference Laboratory Leiden, the Netherlands. Hinterzarten, December 7, 2013 Main problem
More informationExpanding Candidate and Deceased Donor HLA Typing Requirements to Provide Greater Consistency Across Organ Types
At-a-Glance Expanding Candidate and Deceased Donor HLA Typing Requirements to Provide Greater Consistency Across Organ Types Affected/Proposed Policy: 2.8.A (Required Information for Deceased Kidney Donors);
More informationHepatitis After Liver Transplantation: The Role of the Known and Unknown Viruses
Hepatitis After Liver Transplantation: The Role of the Known and Unknown Viruses Mario G. Pessoa,*00 Norah A. Terrault,*00 Linda D. Ferrell, Jill Detmer, Janice Kolberg, Mark L. Collins, Maurene Viele,
More informationRace: A Critical Factor in Organ Donation, Patient Referral and Selection, and Orthotopic Liver Transplantation?
Race: A Critical Factor in Organ Donation, Patient Referral and Selection, and Orthotopic Liver Transplantation? Devin E. Eckhoff,* Brendan M. McGuire, Carlton J. Young,* Marty T. Sellers,* Luc R. Frenette,
More informationCompared efficacy of preservation Solutions in liver transplantation: a long-term graft outcome study from the European Liver Transplant Registry.
12/2013 Compared efficacy of preservation Solutions in liver transplantation: a long-term graft outcome study from the European Liver Transplant Registry. René ADAM, Valérie DELVART, Vincent KARAM, Christian
More informationEffects of HLA-Matched Blood Transfusion for Patients Awaiting Renal Transplantation
CLINICAL AND TRANSLATIONAL RESEARCH Effects of HLA-Matched Blood Transfusion for Patients Awaiting Renal Transplantation Bernadette A. Magee, 1,4 Jeanie Martin, 1 Miceal P. Cole, 1 Kieran G. Morris, 2
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationClinical correlates, outcomes and healthcare costs associated with early mechanical ventilation after kidney transplantation
The American Journal of Surgery (2013) 206, 686-692 Association of Women Surgeons: Clinical Science Clinical correlates, outcomes and healthcare costs associated with early mechanical ventilation after
More informationLong-term prognosis of BK virus-associated nephropathy in kidney transplant recipients
Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK
More informationResearch Article Anti-HLA and Anti-MICA Antibodies in Liver Transplant Recipients: Effect on Long-Term Graft Survival
Clinical and Developmental Immunology Volume 2013, Article ID 828201, 5 pages http://dx.doi.org/10.1155/2013/828201 Research Article Anti-HLA and Anti-MICA Antibodies in Liver Transplant Recipients: Effect
More informationCombined Effect of Donor and Recipient Risk on Outcome After Liver Transplantation: Research of the Eurotransplant Database
LIVER TRANSPLANTATION 21:1486 1493, 2015 ORIGINAL ARTICLE Combined Effect of Donor and Recipient Risk on Outcome After Liver Transplantation: Research of the Eurotransplant Database Joris J. Blok, 1 Hein
More informationArticle. Simultaneous Pancreas Kidney Transplant versus Other Kidney Transplant Options in Patients with Type 2 Diabetes
Article Simultaneous Pancreas Kidney Transplant versus Other Kidney Transplant Options in Patients with Type 2 Diabetes Alexander C. Wiseman* and Jane Gralla Summary Background and objectives Current organ
More informationImpact of HLA Mismatch at First Kidney Transplant on Lifetime With Graft Function in Young Recipients
American Journal of Transplantation 2014; 14: 876 885 Wiley Periodicals Inc. C Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12643
More informationAllocation of deceased donor kidneys. Phil Clayton NSW Renal Group 14 June 2012
Allocation of deceased donor kidneys Phil Clayton NSW Renal Group 14 June 2012 Outline Why study kidney allocation? Equity vs utility Current Australian model Previous work in Australia US allocation research
More informationLong-term Outcomes After Third Liver Transplant
ArtıcLe Long-term Outcomes After Third Liver Transplant C. Burcin Taner, 1 Deniz Balci, 1 Darrin L. Willingham, 1 Andrew P. Keaveny, 1 Barry G. Rosser, 1 Juan M. Canabal, 1 Timothy S. J. Shine, 2 Denise
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationRobert B. Colvin, M.D. Department of Pathology Massachusetts General Hospital Harvard Medical School
Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Robert B. Colvin Transplantation: Friendly organs in a hostile environment Robert B. Colvin,
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationPatient Education Transplant Services. Glossary of Terms. For a kidney/pancreas transplant
Patient Education Glossary of Terms For a kidney/pancreas transplant Glossary of Terms Page 18-2 Antibody A protein substance made by the body s immune system in response to a foreign substance. Antibodies
More informationOPTN/UNOS Histocompatibility Committee Report to the Board of Directors November 12-13, 2014 St. Louis, MO
OPTN/UNOS Histocompatibility Committee OPTN/UNOS Histocompatibility Committee Report to the Board of Directors November 12-13, 2014 St. Louis, MO Dolly Tyan, Ph.D., Chair Robert Bray, Ph.D., Vice Chair
More informationOrgan allocation for liver transplantation: Is MELD the answer? North American experience
Organ allocation for liver transplantation: Is MELD the answer? North American experience Douglas M. Heuman, MD Virginia Commonwealth University Richmond, VA, USA March 1998: US Department of Health and
More informationUser Guide. A. Program Summary B. Waiting List Information C. Transplant Information
User Guide This report contains a wide range of useful information about the kidney transplant program at (FLMR). The report has three main sections: A. Program Summary B. Waiting List Information The
More informationWe have no disclosures
Pulmonary Artery Pressure Changes Differentially Effect Survival in Lung Transplant Patients with COPD and Pulmonary Hypertension: An Analysis of the UNOS Registry Kathryn L. O Keefe MD, Ahmet Kilic MD,
More informationDoes Kidney Donor Risk Index implementation lead to the transplantation of more and higher-quality donor kidneys?
Nephrol Dial Transplant (2017) 32: 1934 1938 doi: 10.1093/ndt/gfx257 Advance Access publication 21 August 2017 Does Kidney Donor Risk Index implementation lead to the transplantation of more and higher-quality
More informationThe future of liver transplantation for viral hepatitis
The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:
More informationIn the United States, the Model for End-Stage Liver. Re-weighting the Model for End-Stage Liver Disease Score Components
GASTROENTEROLOGY 2008;135:1575 1581 Re-weighting the Model for End-Stage Liver Disease Score Components PRATIMA SHARMA,* DOUGLAS E. SCHAUBEL,, CAMELIA S. SIMA,, ROBERT M. MERION,, and ANNA S. F. LOK* *Division
More informationUpdate to the Human Leukocyte Antigens (HLA) Equivalency Tables
Update to the Human Leukocyte s (HLA) Equivalency Tables Sponsoring Committee: Histocompatibility Policy/Bylaws Affected: Policy 2.11.A: Required Information for Deceased Kidney Donors, Policy 2.11.B:
More informationPeter Chang,* Jagbir Gill,* James Dong,* Caren Rose,* Howard Yan,* David Landsberg,* Edward H. Cole, and John S. Gill*
Article Living Donor Age and Kidney Allograft Half-Life: Implications for Living Donor Paired Exchange Programs Peter Chang,* Jagbir Gill,* James Dong,* Caren Rose,* Howard Yan,* David Landsberg,* Edward
More informationSINCE the introduction of Imuran and
Cadaveric Renal Transplantation With Cyclosporin-A and Steroids T. R. Hakala, T. E. Starzl, J. T. Rosenthal, B. Shaw, and S. watsuki SNCE the introduction of muran and prednisone in 1961, and despite the
More informationOverall Goals and Objectives for Transplant Hepatology EPAs:
Overall Goals and Objectives for Transplant Hepatology EPAs: 1. DIAGNOSTIC LIST During the one-year Advanced Pediatric Transplant Hepatology Program, fellows are expected to develop comprehensive skills
More informationAcute rejection and late renal transplant failure: Risk factors and prognosis
Nephrol Dial Transplant (2004) 19 [Suppl 3]: iii38 iii42 DOI: 10.1093/ndt/gfh1013 Acute rejection and late renal transplant failure: Risk factors and prognosis Luis M. Pallardo Mateu 1, Asuncio n Sancho
More informationIncreasing Trends in Transplantation of HCV-positive Livers into Uninfected Recipients
Accepted Manuscript Increasing Trends in Transplantation of HCV-positive Livers into Uninfected Recipients George Cholankeril, MD, Andrew A. Li, MD, Brittany B. Dennis, PhD, Alice E. Toll, MS, Donghee
More informationDonor and Recipient Age and the Allocation of Deceased Donor Kidneys for Transplantation
Donor and Recipient Age and the Allocation of Deceased Donor Kidneys for Transplantation July 26, 2006 Donor and Recipient Age and the Allocation of Deceased Donor Kidneys for Transplantation A paper prepared
More informationQuantitative Survival Model for Short-Term Survival After Adult-to-Adult Living Donor Liver Transplantation
LIVER TRANSPLANTATION 12:904-911, 2006 ORIGINAL ARTICLE Quantitative Survival Model for Short-Term Survival After Adult-to-Adult Living Donor Liver Transplantation Ichiro Tsunematsu, 1 3 Yasuhiro Ogura,
More informationPediatric Liver Transplantation Outcomes in Korea
ORIGINAL ARTICLE Cell Therapy & Organ Transplantation http://dx.doi.org/6/jkms.8..4 J Korean Med Sci 0; 8: 4-47 Pediatric Liver Transplantation Outcomes in Korea Jong Man Kim,, * Kyung Mo Kim,, * Nam-Joon
More informationHepatic Retransplantation in Cholestatic Liver Disease: Impact of the Interval to Retransplantation on Survival and Resource Utilization
Hepatic Retransplantation in Cholestatic Liver Disease: Impact of the Interval to Retransplantation on Survival and Resource Utilization W. RAY KIM, 1 RUSSELL H. WIESNER, 1 JOHN J. POTERUCHA, 1 TERRY M.
More informationHLA-Matched Kidney Transplantation in the Era of Modern Immunosuppressive Therapy
HLA-Matched Kidney Transplantation in the Era of Modern Immunosuppressive Therapy Arun Amatya, MD; Sandy Florman, MD; Anil Paramesh, MD; Anup Amatya, PhD Jennifer McGee, MD; Mary Killackey, MD; Quing Ren,
More informationHepatorenal Syndrome: a Proposal for Kidney After Liver Transplantation (KALT)
LIVER TRANSPLANTATION 13:838-843, 2007 ORIGINAL ARTICLE Hepatorenal Syndrome: a Proposal for Kidney After Liver Transplantation (KALT) Richard Ruiz, Yousri M. Barri, Linda W. Jennings, Srinath Chinnakotla,
More informationKidney Transplant Outcomes for Prolonged Cold Ischemic Times in the Context of Kidney Paired Donation
Kidney Transplant Outcomes for Prolonged Cold Ischemic Times in the Context of Kidney Paired Donation by Yayuk Joffres Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Master
More informationAlemtuzumab Induction in Non-Hepatitis C Positive Liver Transplant Recipients
LIVER TRANSPLANTATION 17:32-37, 2011 ORIGINAL ARTICLE Alemtuzumab Induction in Non-Hepatitis C Positive Liver Transplant Recipients Josh Levitsky, 1,2 Kavitha Thudi, 1 Michael G. Ison, 1,3 Edward Wang,
More informationPretransplant Risk Factors for New-Onset Diabetes Mellitus After Transplant in Pediatric Liver Transplant Recipients
LIVER TRANSPLANTATION 16:1249-1256, 2010 ORIGINAL ARTICLE Pretransplant Risk Factors for New-Onset Diabetes Mellitus After Transplant in Pediatric Liver Transplant Recipients Hung-Tien Kuo, 1,2 Christine
More informationThe Use of HLA /HPA Selected Platelets
The Use of HLA /HPA Selected Platelets Dr Colin Brown PhD FRCPath. Consultant Clinical Scientist Histocompatibility and Immunogenetics HLA and Transfusion Human Leucocyte Antigens HLA Human Platelet Antigens
More informationTransplant Update New Kidney Allocation System Transplant Referral Strategies. Antonia Harford, MD University of New Mexico
Transplant Update New Kidney Allocation System Transplant Referral Strategies Antonia Harford, MD University of New Mexico Financial Disclosures Doctor Harford has received financial support for dialysis
More informationXM-ONE XM-ONE XM-ONE. References XMO_V4.0_100205_CE.EU
Transplantation Cross match Transplantation Cross match XMO_V4._125_CE.EU Manufactured by: ABSORBER AB Address: Drottninggatan 33 SE-13 95 Stockholm, Sweden E-mail: info-ssp@olerup.com Tel: +46 8 5 89
More informationLiver Transplant Pathology a general view
Liver Transplant Pathology a general view Dr S E Davies Addenbrooke s Hospital Cambridge University Hospitals NHS Trust ACP/BSG Meeting Leeds 2012 Liver transplantation When and where? Who and why? How?
More informationLiver transplantation is the only hope for patients with terminal. Indication and Prognosis of Liver Transplantation. Abstract
Indication and Prognosis of Liver Transplantation Jae Won Joh, M.D. Department of General Surgery Sungkyunkwan University School of Medicine Samsung Medical Center E mail: jwjoh@smc.samsung.co.kr Abstract
More informationJ Am Soc Nephrol 14: , 2003
J Am Soc Nephrol 14: 208 213, 2003 Kidney Allograft and Patient Survival in Type I Diabetic Recipients of Cadaveric Kidney Alone Versus Simultaneous Pancreas/Kidney Transplants: A Multivariate Analysis
More informationUsing GIS for Analyzing Optimal Organ Allocation for Liver Transplantation
Using GIS for Analyzing Optimal Organ Allocation for Liver Transplantation September 7, 2011 1 Presenters: Naoru Koizumi 1, Amit Patel 1,Yang Xu 1, Nigel Waters 1, Monica Gentili 2, Ammar Malik 1, Dennis
More informationLiving Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?
Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department
More informationRENAL TRANSPLANTATION HAS
ORIGINAL CONTRIBUTION Arterial Hypertension and Renal Allograft Survival Kevin C. Mange, MD Borut Cizman, MD Marshall Joffe, MD, PhD Harold I. Feldman, MD, MSCE Context Several observational studies have
More information